TTY Biopharm Co Ltd Asset Resilience Ratio
TTY Biopharm Co Ltd asset resilience ratio. TTY Biopharm Co Ltd (4105) has an Asset Resilience Ratio of 4.36% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of TTY Biopharm Co Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of TTY Biopharm Co Ltd (2017–2025)
Asset resilience ratio of TTY Biopharm Co Ltd from 2017 to 2025. This chart shows how TTY Biopharm Co Ltd's Asset Resilience Ratio has changed over time. Read TTY Biopharm Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down TTY Biopharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TTY Biopharm Co Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$509.60 Million | 4.36% |
| Total Liquid Assets | NT$509.60 Million | 4.36% |
Asset Resilience Insights
- Limited Liquidity: TTY Biopharm Co Ltd maintains only 4.36% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
TTY Biopharm Co Ltd Industry Peers by Asset Resilience Ratio
Compare TTY Biopharm Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
TTY Biopharm Co Ltd Asset Resilience Ratio by Year (2017–2025)
TTY Biopharm Co Ltd asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for TTY Biopharm Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.12% | NT$467.74 Million ≈ $14.74 Million |
NT$11.35 Billion ≈ $357.53 Million |
+1.28pp |
| 2024-12-31 | 2.84% | NT$309.01 Million ≈ $9.74 Million |
NT$10.86 Billion ≈ $342.24 Million |
+0.86pp |
| 2023-12-31 | 1.98% | NT$195.54 Million ≈ $6.16 Million |
NT$9.87 Billion ≈ $311.11 Million |
-1.42pp |
| 2022-12-31 | 3.40% | NT$326.86 Million ≈ $10.30 Million |
NT$9.60 Billion ≈ $302.47 Million |
-0.60pp |
| 2021-12-31 | 4.01% | NT$372.65 Million ≈ $11.74 Million |
NT$9.30 Billion ≈ $292.89 Million |
+0.35pp |
| 2020-12-31 | 3.66% | NT$342.40 Million ≈ $10.79 Million |
NT$9.36 Billion ≈ $294.92 Million |
-1.39pp |
| 2019-12-31 | 5.05% | NT$482.62 Million ≈ $15.21 Million |
NT$9.55 Billion ≈ $300.96 Million |
-0.81pp |
| 2018-12-31 | 5.86% | NT$530.83 Million ≈ $16.72 Million |
NT$9.05 Billion ≈ $285.22 Million |
-12.77pp |
| 2017-12-31 | 18.64% | NT$1.77 Billion ≈ $55.82 Million |
NT$9.51 Billion ≈ $299.52 Million |
-- |
About TTY Biopharm Co Ltd
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers … Read more